Trial
NCT02137343
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Amgen
Collaborators
—
Condition
Gastric Cancer
Intervention
Rilotumumab
Why stopped
All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-04-04